Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Osimertinib, Lazertinib, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
20
States / cities
Goodyear, Arizona • Yuma, Arizona • Long Beach, California + 17 more
Active, not recruiting Phase 2 Interventional Results available

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

NCT05663866
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Dexamethasone, Montelukast, Methotrexate, Amivantamab, Lazertinib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Fountain Valley, California • Fairfax, Virginia • Renton, Washington
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab IV, Amivantamab SC, Lazertinib, Doxycycline, Minocycline, Clindamycin, Chlorhexidine, Noncomedogenic skin moisturizer, Ruxolitinib, Tacrolimus, Zinc gluconate, Propranolol, Timolol, Clobetasol
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
28
States / cities
Chandler, Arizona • Duarte, California • Fullerton, California + 25 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Amivantamab, Lazertinib, Chemotherapy: Pemetrexed, Chemotherapy: Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
150
States / cities
Daphne, Alabama • Huntsville, Alabama • Goodyear, Arizona + 117 more
Conditions
Advanced or Metastatic Colorectal Cancer
Interventions
Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 9 more
Recruiting No phase listed Observational

A Study in Non-Small Cell Lung Cancer

NCT07174388
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
N-Power Medicine
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Monterey, California • Dover, Delaware • Milford, Delaware + 5 more
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
41
States / cities
Chandler, Arizona • Fullerton, California • Los Angeles, California + 36 more
Conditions
Carcinoma, Non-small-Cell Lung
Interventions
Amivantamab, Lazertinib, Carboplatin, Pemetrexed, Direct Oral Anticoagulant (DOAC), Low Molecular Weight Heparin (LMWH)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
26
States / cities
La Jolla, California • Orange, California • Stanford, California + 21 more
Conditions
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions
Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 28 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Carboplatin, Pemetrexed
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
18
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 12 more
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Amivantamab, Pembrolizumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
15
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 12 more
Conditions
Non-small Cell Lung Cancer
Interventions
Amivantamab, Tepotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Colorectal Neoplasms
Interventions
Amivantamab, Cetuximab, Bevacizumab, 5-fluorouracil, Leucovorin calcium/Levoleucovorin, Irinotecan
Biological · Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
70
States / cities
Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 59 more
Conditions
Lung Cancer, Non Small Cell Lung Cancer
Interventions
Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • Ann Arbor, Michigan
Conditions
Esophagogastric Cancer
Interventions
Amivantamab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
9
States / cities
Irvine, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Biological · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
248
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 211 more
Conditions
Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma
Interventions
Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Tucson, Arizona • Ann Arbor, Michigan • Omaha, Nebraska
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Active, not recruiting Phase 2 Interventional Results available

Amivantamab in Adenoid Cystic Carcinoma

NCT05074940
Conditions
Salivary Gland Cancer
Interventions
Amivantamab
Drug
Lead sponsor
Trisha Wise-Draper
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Cetrelimab, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Alamitos, California + 3 more
Conditions
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms, Neoplasms by Site, Lung Diseases, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Adenocarcinoma, Carcinoma, Neoplasms by Histologic Type, EGFR Exon 20 Mutation, EGFR Exon 20 Insertion Mutation, EGFR Activating Mutation, Antineoplastic Agents, Metastatic Lung Cancer, Brain Metastases, EGFR-mutated NSCLC, EGFR Atypical Mutations, Including G719X and L861Q
Interventions
BLU-451, Carboplatin, Pemetrexed
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 8 more
Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
Lazertinib, Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF), Amivantamab Intravenous
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Duarte, California • Irvine, California • Long Beach, California + 13 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Amivantamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 2 more
Conditions
Neoplasms
Interventions
Ami-LC-MD, Ami-LC, Ami-HC, Ami-HC-CF
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
5
States / cities
West Hollywood, California • Indianapolis, Indiana • New York, New York + 2 more